Beyer-Westendorf J, et al. Two-year outcomes of patients with atrial fibrillation treated with rivaroxaban: results from RIVER registry. 2021 ESC Congress.
Abella F, et al. Direct oral anti-coagulants in patients with atrial fibrillation and bioprosthetic valve: a meta-analysis of randomized controlled trials. 2021 ESC Congress.
Pastor, et al. Oral anticoagulation therapy with rivaroxaban in elderly patients with atrial fibrillation. Results from EMIR study. 2021 ESC Congress.
Lee SR, et al. Net clinical benefit of direct oral anticoagulants in very elderly and high bleeding risk patients with atrial fibrillation who are often excluded from oral anticoagulation therapy: a nationwide popul. 2021 ESC Congress.
Rodriguez Garcia LA, et al. Renal decline in patients with atrial fibrillation treated with rivaroxaban or warfarin: a population-based cohort study in the United Kingdom. 2021 ESC Congres.
Wartanian A, et al. DOAC versus warfarin in patients with atrial fibrillation and stage IV-V chronic kideny disease including patients on dialysis. 2021 ESC Congress.